Member Info for B2HS2L

"The remedial work on the compressor engine was successfully completed in the afternoon of 5(th) July"

My expectation would be that it was fixed under the terms of a full warranty, at no cost to the company.

Davand -

You mention on the yourgene bb that 'Ranger uses Illumina machinery'.

Can you expand on that please, if not not probs.

FWIW, the Novacyt acting CEO James McCarthy is also the CFO.

He has overseen the headcount restructure and the closure of two group companies,

after agreeing to hold both positions (10.11.2022).

https://twitter.com/novacytgroup/status/1676520835249520641

at last, we can see tom major's much vaunted latest novacyt video concerning versalab.

great shame paul doesn't mention versalab, and 'versalab' doesn't appear in the subtitles,

or provide a website or contact email / phone number anywhere.

i don't work in marketing or sales.

why aren't these obvious omissions visible to the staff who do?

this is money wasted. #****edoffemoji

View many shares were bought and sold at exactly 11:06:47 today. None of them automated (apparently).

The thread in which these links were identified has been removed for reason(s) unknown.

Myself and another poster identified two stories the same:

"Missed Nvidia? This London A.I Stock Could Jump Over 1,000%"

https://daily-finance.news/?p=3598&gclid=EAIaIQobChMImZXUhKP1_wIV6jyzAB0VhAA_EAEYASAAEgL15fD_BwE

https://world-finance-news.com/?p=5612&gclid=EAIaIQobChMIuqK0-OT0_wIVRMLtCh3HZgpWEAAYASAAEgL8zfD_BwE

The thread in which these posts were identified has been removed for reason(s) unknown.

From RNS: "to be effected by means of a Scheme of Arrangement under Part 26 of the Companies Act 2006"

https://legalvision.co.uk/corporations/part-26a-restructuring-plan/

Provided for clarity.

Https://www.scientificlabs.co.uk/search/primerdesign?page=1&sortby=DEFAULT

Primerdesign prices through scientificlabs visible here.

Here's hoping this is beneficial for both parties, but we could do with some introductory offers here.

Https://twitter.com/NovacytGroup/status/1673632371655036933

Its unlikely I think, any links within this text are provided to amplify any of the specific technology used in any future Novacyt biosensor that makes it to market.

More a case of bringing attention to the various types of technology mushrooming under the subject of biosensors.

A previous RNS states

"Plan will start with a series of focused, investigator-led/Synairgen-sponsored studies, using existing resources, which are intended to lead towards a Phase 3 registrational programme. Preparation is underway for these focused trials to initiate in H2 2023."

FWIW - An interested party or parties appear to be saying that from the previous Phase 2 and 3 results, we need further focused trials to be successfully complete before we discuss a 'Phase 3 registrational programme' further.

I'm certain no further pay rises are in order, retroactive or not, and we need to see a successful Phase 3 trial completed before BoD pay rises are justified.

If that means no pay rises next year either, then the BoD needs to act with more haste than they have done last year or this.

Paladin -

"I will stick with my cart and horse analogy. Why not wait for the company to deliver a clinical outcome to significantly increase the share price first? A share price increase, to 40-50p say, would get Synairgen back on track"

Afraid you are putting the cart before the horse here, because nobody knows what has to be performed to achieve that share price.

Best to stick to the fact that the current share price does not warrant a pay rise for board members, because we aren't deriving income from a successful clinical outcome, only then should pay rises be voted on, as they are remunerated well enough for the current mess the company is in.

Banging on the door of profitability.

If you are right Wilson, I think only JW will be surprised by the feedback provided.

If that's the case then no pay rise possible .

HAHA!!

T_P

Q1 would imply that these persons usefulness is being kept ready for a sunny day that never comes.

All the ducks have been aligned for too long for continued employment to make sense, unless news drops soon.

They've been more free with info onthis product than they normally are, despite it possibly being a market disruptor.

"Development of two products has started" - so there is room for a few more down the road a little?

Whatever, yes a risk that Eluceda don't deliver.

"each gate is a stop and evaluate with a decision to progress" - lets stop there - they must have been through all these events at a high level and are confident that when they reach each gate, they are confident they will have the software / capability / hardware necessary to progress beyond each.

It's high stakes stuff, but for a product that might be a game changer.

Somehow I think we will be a little lucky to see a product launch in early 2024, but I find all the info they have provided more a statement of intent, certainly much more than normal.

In house green shoots?

Temporary QC and QA jobs ending around early 2024 may go some way to satisfying this, as it shows the project plan is currently on course. Lets hope they find these staff soon.

Google - Stage-gate:

"Stage Gate, also known as Phase Gate, is a widely used project management methodology designed to guide a project from its inception to completion."

27.04.2023 RNS contains

"In January 2023 Novacyt entered into an exclusive development agreement with Eluceda Ltd, a specialist developer of electrochemical sensors, to develop novel biosensor technology in the fields of human and animal in vitro diagnostics, life science research and animal speciation. Development of two products has started and the first product is expected to launch early in 2024."

Management has provided a launch date via the public domain.

However we are wary of such dates at Novacyt as a launch date is a rarity, especially one as far away as Jan 24.

Jan 24 is believable until otherwise negated by management, but as they have been so bold as to announce this publically I don't see why they should not be held accountable, so it's tangible and not lost in the wings.

Kaeren, - I don't think management are in a position to advise on the specifics of any new project, particularly one that might qualify as a market disrupting product.

From transcript of Half year 2022 results presentation :

"... In terms of business development, let me give you a little bit more colour of what we've delivered, against these three subheadings that we shared with you earlier in the year. Number one on innovation, which is earlier technology where we're seeking to develop disruptive technology, we're advancing our efforts on a co-development of a point-of-care biosensor platform. That's early, but it's, you know, it's advancing towards stage gates... "

We've had more info and time scales now, so my expectations are high (higher than normal) here.

A go-to-market (GTM) strategy is a plan that details how an organization can engage with customers to convince them to buy their product or service and to gain a competitive advantage. A GTM strategy includes tactics related to pricing, sales and channels, the buying journey, new product or service launches, product rebranding or product introduction to a new market.

+++

Thanks Larry / kearen. - Makes you wonder what Novacyt got for their money though. 🤔